ABSTRACT BACKGROUND Light-chain amyloidosis (AL) with cardiac involvement carries a poor prognosis; median untreated
A myloidosis is a disease in which misfolded proteins aggregate into fibrils, deposit in the extracellular matrix, and result in organ dysfunction (1) . Cardiac involvement almost exclusively develops from the deposition of either transthyretin or immunoglobulin light chains (AL), leading to a restrictive cardiomyopathy. AL amyloidosis, a disease of clonal plasma cells, can be rapidly fatal, with a median survival of 6 months without treatment if cardiac involvement is diagnosed (2) . Heart failure at presentation carries the worst prognosis compared with other manifestations (3), yet heart failure symptom assessment is underrepresented in current analyses of treatment effects. Bortezomib, when added to an alkylating agent and dexamethasone (BDexþAA), is thought to work synergistically in arresting the life cycle of clonal plasma cells (7) .
These studies included a varied number of patients with cardiac involvement as defined by the Mayo stage, which is based upon the biomarkers troponin T, N-terminal of the prohormone of brain natriuretic peptide (NT-proBNP), and the free light-chain burden (8) . However, few have assessed the presence or severity of heart failure symptoms. Although
BDexþAA has emerged as the treatment of choice in all-comers with AL amyloidosis due to improved biomarker response rates, there are no direct mortality data confirming benefit in patients with symptomatic heart failure. We sought to evaluate the effect of BDexþAA as a first-line treatment strategy on mortality in patients presenting with symptomatic heart failure from AL cardiac amyloidosis. The initial therapeutic regimen was BDexþAA in Kaplan-Meier curve representing the association between treatment regimen and all-cause mortality. There was a significant association between treatment regimen and survival (p < 0.001), with the lowest mortality seen in the bortezomib, dexamethasone, and alkylating agent (BDexþAA) cohort. an overall response rate of 42% and median survival of 7 months (15). Indeed, NT-proBNP level was also highly predictive of mortality in our cohort. Additional case series have described the response rates of BDexþAA in all-comers with AL amyloidosis (16, 17) , and those at high cardiac risk (18) . It is important to note that in these as well as several other studies, hematologic response predicts improved survival.
METHODS
There has been some concern with bortezomib in patients with cardiac involvement. There have been post-marketing reports of fluid retention in patients treated for amyloidosis, and trials in myeloma excluded patients with congestive heart failure (19, 20) . Our current report strengthens the TRANSLATIONAL OUTLOOK: Future studies of novel chemotherapeutic agents, particularly those with fibril clearing properties, are needed in patients with symptomatic heart failure due to light-chain amyloidosis given the continued poor prognosis in this disease.
